Sunovion Pharmaceuticals, a US subsidiary of Japanese pharma company Sumitomo Dainippon (TYO: 4506), has revealed positive top-line data from its Phase III trial of Parkinson’s disease (PD) candidate APL-130277.
The apomorphine sublingual film is being developed to treat ‘off episodes,’ periods where the gold standard medication levodopa has worn off, causing worsening of Parkinsonian symptoms.
Such episodes are experienced by up to 60% of people with PD, and can become more severe over time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze